In conclusion, our current data underlines several advantages of TGNs in targeting HER2-positive breast cancers and exhibits promising anti-tumor activity in vitro and vivo. Porphyrin and trastuzumab conjugating allows easy nanocomplex detection and specific binding onto HER2 over-expressed cell surface receptors. Here, ERBB2 is linked to breast cancer.